Novo Nordisk A/S (NYSE:NVO) on Monday presented results from its Phase 3 REIMAGINE 1-3 trials, showing that investigational treatment CagriSema significantly reduced both HbA1c and body weight in adults with Type 2 diabetes.

The once-weekly therapy combines a novel amylin analog with a GLP-1 receptor agonist. Across all three studies, CagriSema met the primary endpoint of reducing HbA1c and achieved confirmatory secondary endpoints related to weight loss.

The company evaluated CagriSema at doses of 2.4 mg/2.4 mg and 1 mg/1 mg administered once weekly. Results demonstrated significant improvements in blood sugar control and body weight compared with study comparators.

Read Also:

Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game'

Zenagamtide Shows Dose-Dependent Benefits

On Saturday, Novo Nordisk also shared new Phase 2 data for investigational drug zenagamtide, also known as amycretin.

The study met its primary endpoint, showing ...